Menu Back toS11-How-Will-the-Development-and-NDA-Activities-in-Japan-Change-in-View-of-the-Future-of-AI-Translation

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S11] How Will the Development and NDA Activities in Japan Change in View of the Future of AI Translation?

Session Chair(s)

Michio  Tanaka

Michio Tanaka

  • Executive Officer, Division Vice president, Science & Data Technology Division
  • AstraZeneca K.K., Japan
Following 2018 Japan annual meeting, the current status of AI translation in the pharmaceutical field will be reviewed. We will discuss how industrygovernment- academia collaboration should be promoted to further improve quality of AI translation, based on the status and issues of quality improvement before and after adaptation in pharmaceutical companies and success cases in other industries.


Kiyoshi  Kinoshita, PhD

R&D Head Club's WGs report: Quality-improvement before and after Adaptation

Kiyoshi Kinoshita, PhD

  • Manager, Regulatory Affairs, Area Japan Development
  • MSD K.K., Japan
Toshiyuki  Shigematsu

Key for Success of Machine Translation - How to Perform Post-Edit Effectively

Toshiyuki Shigematsu

  • Medical Writer
  • Novartis Pharma Co Ltd, Japan
Yusuke  Asoh

A Case of Company-wide Introduction of AI Translation Technology -Background, Process and Future Prospects

Yusuke Asoh

  • Manager, IT Strategy Department
  • Daiichi Sankyo Co., Ltd, Japan